Guide
EU GDP: Wholesale Distribution that an MHRA or HPRA Inspector Would Sign Off
Good Distribution Practice for medicinal products for human use, set out in the European Commission Guidelines of 5 November 2013 (2013/C 343/01), governs every wholesale distribution activity for licensed medicines in the EU and UK. Inspections by MHRA, HPRA, ANSM and other competent authorities are unforgiving on the same handful of clauses — Responsible Person duties, temperature mapping, qualified suppliers and customers, falsified-medicines controls, and deviation handling. This guide walks through the structure of the guidelines, the artefacts an inspector pulls on entry, and a realistic path to a Wholesale Distribution Authorisation (WDA) inspection you would actually welcome. It is written for Responsible Persons, QA managers, warehouse leads, and compliance officers at wholesale distributors, 3PLs, and pharma manufacturers operating their own distribution.
Start free trial Free trial, no credit card, onboard in days, not months.
Chapter 1: Quality Management and the Responsible Person
Chapter 1 requires a documented quality system covering all aspects of distribution and explicitly names the Responsible Person (RP) as continuously available and responsible for the implementation and maintenance of the quality system. The RP must have the authority, the resources, and the documented competence to fulfil the role — including the authority to make decisions independently of commercial pressures, to recall product, to suspend distribution, and to refuse release of suspect product. The RP delegation in writing, the RP qualifications on file, and evidence that the RP actually exercises authority (signed releases, signed deviations, signed recall decisions) are the entry-level evidence inspectors check first.
Chapter 2: Personnel, training, and hygiene
Chapter 2 requires that all personnel involved in distribution are competent, trained for their duties, and that training is documented and effective. The training must cover GDP, the role-specific procedures, hygiene where relevant, and the identification of falsified medicines for personnel handling product. Effectiveness must be verified — training records that show attendance but not comprehension are a recurring finding. Build training as a controlled curriculum per role, with periodic re-training driven by procedure changes or competence assessments, and evidence of comprehension (test, observation, sign-off) attached to each record.
Chapter 3: Premises and equipment, with temperature mapping
Chapter 3 covers the warehouse — segregation of damaged/recalled/suspect product, controlled access, suitable equipment, and crucially, temperature control. Cold-chain (2-8°C) and controlled-room-temperature (15-25°C) storage areas must be temperature-mapped, with the mapping documented, the monitoring devices calibrated, the monitoring intervals risk-justified, and alarms tested. The most common finding is a temperature-mapping exercise done at WDA grant and never repeated — even though the layout, racking, or HVAC has changed. Repeat the mapping after significant changes, and on a defined periodic cadence (typically every two to three years for static facilities).
Chapter 4: Documentation that proves what happened
Chapter 4 requires documentation covering all activities relevant to GDP — procedures, instructions, records, contracts, qualifications, transactions — retained for the period specified by national legislation (typically five years in most member states, longer in some). Records must be made at the time of the activity, legible, retrievable, and protected from alteration. Electronic records must have audit trail and access control equivalent to Part 11 / Annex 11 expectations. The recurring failure mode is a documentation system that captures the right data but doesn't link it — a temperature excursion record that exists but doesn't reference the affected stock movements, a deviation that exists but doesn't show the corrective action taken.
Chapter 5: Operations — qualified suppliers and customers
Chapter 5 requires that medicinal products are only sourced from holders of a manufacturing or wholesale distribution authorisation and only supplied to persons who themselves hold an authorisation or are entitled to receive medicinal products for retail or supply (pharmacies, hospitals, certain healthcare professionals). The supplier and customer qualification has to be documented, periodically re-verified (typically against the EMA EudraGMDP database for EU MIAs and WDAs), and tied to the actual transactions. Companies who qualify customers at onboarding but never re-check are the typical finding — a customer's WDA can be suspended without their counterparties noticing.
Falsified medicines, returns and recalls
Chapter 5 and Chapter 6 together cover the falsified-medicines safeguards (alongside the Falsified Medicines Directive 2011/62/EU and Delegated Regulation 2016/161), the handling of returns (including verification before resale), and recall procedures. The FMD obligations — verification of the unique identifier at the point of dispense, decommissioning, and supply-chain risk-based verification by wholesalers — interlock with GDP and are typically inspected together. Returns from non-licensed sources cannot be returned to saleable stock; returns from licensed sources require documented verification of storage conditions during the return journey. Recall procedures must be tested via a mock recall, time-bounded, and signed by the RP.
Chapters 7 to 9: outsourced activities, self-inspection, transport
Chapter 7 covers outsourced activities — every contract must specify GDP responsibilities, the contract acceptor must demonstrate suitability (typically through an audit), and the contract giver retains responsibility. Chapter 8 requires a self-inspection programme covering all aspects of GDP at a defined frequency, with documented findings and corrective actions. Chapter 9 covers transport — qualified routes, temperature control during transit, validated packaging for cold chain, and documented handover. Self-inspection coverage, contract-acceptor audit evidence, and transport qualification records are the three places where small wholesalers consistently lose points in inspection.
Where this lives in V5 Ultimate
The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.
Modules that do the work
Quality management
GDP-aligned QMS with the Responsible Person as a structured role.
Supplier & customer qualification
Live EudraGMDP verification on every transaction.
Traceability
Lot-level genealogy from receipt to dispatch, integrated with FMD.
Recall & returns
Mock recalls timed and signed by the RP; returns gate by source and FMD status.
Deviations & self-inspection
Temperature excursions and self-inspection findings routed to the RP.
Document control
GDP procedures, training and contract-acceptor evidence under version control.
Industries this hits hardest
Frequently asked
Does GDP apply to investigational medicinal products (IMPs)?
The EU Good Distribution Practice guidelines specifically cover medicinal products with marketing authorisation. Investigational medicinal products are governed by their own distribution requirements (linked to GCP and the Clinical Trial Regulation), although many wholesalers handle both and apply GDP principles to IMP distribution by extension. The applicable framework for any specific IMP should be confirmed with the sponsor and the receiving competent authority.
How does GDP relate to GMP for manufacturer-owned distribution?
A manufacturer distributing their own products operates the distribution under their Manufacturing and Importation Authorisation (MIA) and GMP, not a separate WDA — but the GDP principles still apply to the distribution activities. Many manufacturers structure the distribution organisation under both GMP for the manufacturing-adjacent activities and GDP for the broader distribution operations, with the Qualified Person and Responsible Person roles separately assigned.
What is the difference between RP, RPi, and QP?
The Responsible Person (RP) is the GDP role under a WDA. The Responsible Person for Import (RPi), introduced post-Brexit by MHRA in the UK, covers the import of human medicines from the EU/EEA into Great Britain. The Qualified Person (QP) is the GMP role under an MIA and is responsible for batch certification. They are distinct roles with distinct qualifications, and the same individual usually does not hold more than one of them for the same operation.
How often are GDP inspections?
Routine GDP inspections by competent authorities are typically on a two-to-three-year cycle for low-risk wholesalers and more frequent for high-risk activities (cold-chain, controlled drugs, parallel import). Inspections can also be unannounced or triggered by complaints, recalls, or pharmacovigilance signals. Plan readiness as a continuous state, not a pre-inspection scramble.
See it on your shop floor.
Free trial, no credit card, onboard in days, not months.